COVID-19 vaccine developed by China's CanSino to continue advancing phase-3 trials: report
BEIJING - China's CanSino Biologics Inc has got green light to continue phase-3 trials of its COVID-19 vaccine with the support of findings of an independent data monitoring committee, said recent media reports.
The independent committee "found the drugmaker's COVID-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," Reuters cited the biopharmaceutical company to report on Monday.
"No adverse events related to the vaccine had occurred," the report said.
The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc and the Academy of Military Sciences in China.
CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China's Ministry of Science and Technology, said in September last year.
- Lotus sanctuary dazzles at wetland park in Chongqing
- Nearly 5,700 residents relocated amid heavy rain in Jizhou, Tianjin
- China to offer nationwide childcare subsidies
- China sees better air, water quality in H1
- Heavy-ion accelerator integrating into cancer treatment in China
- Duty-free complex welcomes cats and dogs in Hainan
